# 2013

Glasgow, Scotland

I-01 Andrijana RadivojevicEnhancing population PK modeling efficiency using an integrated workflowWednesday 10:05-11:40 |

I-02 Gauri RaoA Proposed Adaptive Feedback Control (AFC) Algorithm for Linezolid (L) based on Population Pharmacokinetics (PK)/Pharmacodynamics (PD)/Toxicodynamics(TD)Wednesday 10:05-11:40 |

I-03 Sylvie RetoutA drug development tool for trial simulation in prodromal Alzheimer’s patient using the Clinical Dementia Rating scale Sum of Boxes score (CDR-SOB).Wednesday 10:05-11:40 |

I-04 Philippe JacqminConstructing the disease trajectory of CDR-SOB in Alzheimer’s disease progression modellingWednesday 10:05-11:40 |

I-05 Rachel RoseApplication of a Physiologically Based Pharmacokinetic/Pharmacodynamic (PBPK/PD) Model to Investigate the Effect of OATP1B1 Genotypes on the Cholesterol Synthesis Inhibitory Effect of RosuvastatinWednesday 10:05-11:40 |

I-06 Elisabeth RouitsPopulation pharmacokinetic model for Debio 1143, a novel antagonist of IAPs in cancer treatment Wednesday 10:05-11:40 |

I-07 Alberto RussuSecond-order indirect response modelling of complex biomarker dynamicsWednesday 10:05-11:40 |

I-08 Teijo SaariPharmacokinetics of free hydromorphone concentrations in patients after cardiac surgeryWednesday 10:05-11:40 |

I-09 Tarjinder SahotaReal data comparisons of NONMEM 7.2 estimation methods with parallel processing on target-mediated drug disposition modelsWednesday 10:05-11:40 |

I-10 Maria Luisa SarduTumour Growth Inhibition In Preclinical Animal Studies: Steady-State Analysis Of Biomarker-Driven Models.Wednesday 10:05-11:40 |

I-11 Emilie SchindlerPKPD-Modeling of VEGF, sVEGFR-1, sVEGFR-2, sVEGFR-3 and tumor size following axitinib treatment in metastatic renal cell carcinoma (mRCC) patientsWednesday 10:05-11:40 |

I-12 Alessandro SchipaniPopulation pharmacokinetic of rifampicine in Malawian children.Wednesday 10:05-11:40 |

I-13 Henning SchmidtThe “SBPOP Package”: Efficient Support for Model Based Drug Development – From Mechanistic Models to Complex Trial Simulation Wednesday 10:05-11:40 |

I-14 Stephan SchmidtMechanistic Prediction of Acetaminophen Metabolism and Pharmacokinetics in Children using a Physiologically-Based Pharmacokinetic (PBPK) Modeling ApproachWednesday 10:05-11:40 |

I-15 Rik SchoemakerScaling brivaracetam pharmacokinetic parameters from adult to pediatric epilepsy patientsWednesday 10:05-11:40 |

I-16 Seonghae YoonPopulation pharmacokinetic analysis of two different formulations of tacrolimus in stable pediatric kidney transplant recipientsWednesday 10:05-11:40 |

I-17 Catherine SherwinDense Data - Methods to Handle Massive Data Sets without CompromiseWednesday 10:05-11:40 |

I-18 Giovanni SmaniaIdentifying the translational gap in the evaluation of drug-induced QTc interval prolongationWednesday 10:05-11:40 |

I-19 Alexander SolmsTranslating physiologically based Parameterization and Inter-Individual Variability into the Analysis of Population PharmacokineticsWednesday 10:05-11:40 |

I-20 Hankil SonA conditional repeated time-to-event analysis of onset and retention times of sildenafil erectile responseWednesday 10:05-11:40 |

I-21 Heiner SpethReferenced Visual Predictive Check (rVPC)Wednesday 10:05-11:40 |

I-22 Michael SpigarelliTitle: Rapid Repeat Dosing of Zolpidem - Apparent Kinetic Change Between DosesWednesday 10:05-11:40 |

I-23 Christine StaatzDosage individulisation of tacroliums in adult kidney transplant recipientsWednesday 10:05-11:40 |

I-24 Gabriel StillemansA generic population pharmacokinetic model for tacrolimus in pediatric and adult kidney and liver allograft recipientsWednesday 10:05-11:40 |

I-25 Elisabet StørsetPredicting tacrolimus doses early after kidney transplantation - superiority of theory based modelsWednesday 10:05-11:40 |

I-26 Fran StringerA Semi-Mechanistic Modeling approach to support Phase III dose selection for TAK-875 Integrating Glucose and HbA1c Data in Japanese Type 2 Diabetes Patients Wednesday 10:05-11:40 |

I-27 Eric StrömbergFIM approximation, spreading of optimal sampling times and their effect on parameter bias and precision.Wednesday 10:05-11:40 |

I-28 Herbert StruemperPopulation pharmacokinetics of belimumab in systemic lupus erythematosus: insights for monoclonal antibody covariate modeling from a large data setWednesday 10:05-11:40 |

I-29 Elin SvenssonIndividualization of fixed-dose combination (FDC) regimens - methodology and application to pediatric tuberculosisWednesday 10:05-11:40 |

I-30 Eva SverrisdóttirModelling analgesia-concentration relationships for morphine to evaluate experimental pain modelsWednesday 10:05-11:40 |

I-31 Maciej SwatPharmML – An Exchange Standard for Models in PharmacometricsWednesday 10:05-11:40 |

I-32 Amit TanejaFrom Behaviour to Target: Evaluating the putative correlation between clinical pain scales and biomarkers.Wednesday 10:05-11:40 |

I-33 Joel TarningThe population pharmacokinetic and pharmacodynamic properties of intramuscular artesunate and quinine in Tanzanian children with severe falciparum malaria; implications for a practical dosing regimen.Wednesday 10:05-11:40 |

I-34 David TernantAdalimumab pharmacokinetics and concentration-effect relationship in rheumatoid arthritisWednesday 10:05-11:40 |

I-35 Adrien TessierHigh-throughput genetic screening and pharmacokinetic population modeling in drug developmentWednesday 10:05-11:40 |

I-36 Iñaki F. TrocónizModelling and simulation applied to personalised medicineWednesday 10:05-11:40 |

I-37 Nikolaos TsamandourasA mechanistic population pharmacokinetic model for simvastatin and its active metabolite simvastatin acidWednesday 10:05-11:40 |

I-38 Sebastian UeckertAD i.d.e.a. – Alzheimer’s Disease integrated dynamic electronic assessment of CognitionWednesday 10:05-11:40 |

I-39 Wanchana UngphakornDevelopment of a Physiologically Based Pharmacokinetic Model for Children with Severe MalnutritionWednesday 10:05-11:40 |

I-40 Elodie ValadePopulation Pharmacokinetics of Emtricitabine in HIV-1-infected PatientsWednesday 10:05-11:40 |

I-41 Georgia ValsamiPopulation exchangeability in Bayesian dose individualization of oral BusulfanWednesday 10:05-11:40 |

I-42 Sven van DijkmanPredicting antiepileptic drug concentrations for combination therapy in children with epilepsy.Wednesday 10:05-11:40 |

I-43 Coen van HasseltDesign and analysis of studies investigating the pharmacokinetics of anti-cancer agents during pregnancyWednesday 10:05-11:40 |

I-44 Anne van RongenPopulation pharmacokinetic model characterising the influence of circadian rhythm on the pharmacokinetics of oral and intravenous midazolam in healthy volunteers Wednesday 10:05-11:40 |

I-45 Marc VandemeulebroeckeLiterature databases: integrating information on diseases and their treatments.Wednesday 10:05-11:40 |

I-46 Nieves Velez de MendizabalA Population PK Model For Citalopram And Its Major Metabolite, N-desmethyl Citalopram, In RatsWednesday 10:05-11:40 |

I-47 An VermeulenPopulation Pharmacokinetic Analysis of Canagliflozin, an Orally Active Inhibitor of Sodium-Glucose Co-Transporter 2 (SGLT2) for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM)Wednesday 10:05-11:40 |

I-48 Marie ViganModelling the evolution of two biomarkers in Gaucher patients receiving enzyme replacement therapy.Wednesday 10:05-11:40 |

I-49 Paul VigneauxExtending Monolix to use models with Partial Differential EquationsWednesday 10:05-11:40 |

I-50 Winnie VogtPaediatric PBPK drug-disease modelling and simulation towards optimisation of drug therapy: an example of milrinone for the treatment and prevention of low cardiac output syndrome in paediatric patients after open heart surgeryWednesday 10:05-11:40 |

I-51 Max von KleistSystems Pharmacology of Chain-Terminating Nucleoside AnalogsWednesday 10:05-11:40 |

I-52 Camille VongSemi-mechanistic PKPD model of thrombocytopenia characterizing the effect of a new histone deacetylase inhibitor (HDACi) in development, in co-administration with doxorubicin.Wednesday 10:05-11:40 |

I-53 Katarina VučićevićTotal plasma protein and haematocrit influence on tacrolimus clearance in kidney transplant patients - population pharmacokinetic approachWednesday 10:05-11:40 |

I-54 Bing WangPopulation pharmacokinetics and pharmacodynamics of benralizumab in healthy volunteers and asthma patients Wednesday 10:05-11:40 |

I-55 Jixian WangDesign and analysis of randomized concentration controlled Wednesday 10:05-11:40 |

I-56 Franziska WeberA linear mixed effect model describing the expression of peroxisomal ABCD transporters in CD34+ stem cell-derived immune cells of X-linked Adrenoleukodystrophy and control populationsWednesday 10:05-11:40 |

I-57 Sebastian WeberPK/PD assessment of tacrolimus nephrotoxicity in liver transplantationWednesday 10:05-11:40 |

I-58 Mélanie WilbauxA drug-independent model predicting Progression-Free Survival to support early drug development in recurrent ovarian cancerWednesday 10:05-11:40 |

I-59 Dan WrightBayesian dose individualisation provides good control of warfarin dosing.Wednesday 10:05-11:40 |

I-60 Klintean WunnapukPopulation analysis of paraquat toxicokinetics in poisoning patientsWednesday 10:05-11:40 |

I-61 Rujia XiePopulation PK-QT analysis across Phase I studies for a p38 mitogen activated protein kinase inhibitor – PH-797804Wednesday 10:05-11:40 |

I-62 Shuying YangFirst-order longitudinal population model of FEV1 data: single-trial modeling and meta-analysisWednesday 10:05-11:40 |

I-63 Jiansong YangPractical diagnostic plots in aiding model selection among the general model for target-mediated drug disposition (TMDD) and its approximationsWednesday 10:05-11:40 |

I-64 Rui ZhuPopulation-Based Efficacy Modeling of Omalizumab in Patients with Severe Allergic Asthma Inadequately Controlled with Standard TherapyWednesday 10:05-11:40 |